Shangqi Li

TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study

Jie Chen, Xiaobo Wang, Lequn Li, 2024, BMC cancer.